Cyclic progestin therapy for the management of mastopathy and mastodynia

Gynecological Endocrinology

Volumn 15, Issue SUPPL. 6, 2001, Pages 37-43

  Winkler, U H ^a   Schindler, A E ^a   Brinkmann, U S ^a   Ebert, C ^b   Oberhoff, C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Mastodynia; Mastopathy; Progestin treatment

Indexed keywords

DYDROGESTERONE; ESTRADIOL; GESTAGEN; MEDROGESTONE; PROGESTERONE;

ADULT; ARTICLE; BLOOD; BREAST DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; MIDDLE AGED; PAIN; PALPATION; PATHOPHYSIOLOGY; PERIODICITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; BREAST DISEASES; DOUBLE-BLIND METHOD; DYDROGESTERONE; ESTRADIOL; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMANS; LUTEAL PHASE; MEDROGESTONE; MENSTRUAL CYCLE; MIDDLE AGED; PAIN; PALPATION; PERIODICITY; PROGESTERONE; PROGESTINS; TREATMENT OUTCOME;

EID: 0345132370     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.15.s6.37.43     Document Type: Article

References (28)

1. Junkermann H. Diagnostik gutartiger Brusterkrankungen Klinik. Gynäkologe 1989;22: 226-9
2. Bässler JR. Pathologie der Brustdrüse. Berlin: Springer, 1978
3. Wang DY, Fentinam IS. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat 1985;6:5-36
4. Pollow K, Boquoi E, Baumann J, et al. Comparison of the in vitro conversion of estradiol-17beta to estrone of normal and neoplastic human breast tissue. Mol Cell Endocrinol 1977;6:333-48
5. Mauvais-Jarvis P, Sitruk-Ware R, Kuttenn F. Luteal phase defect and breast cancer genesis. Breast Cancer Res Treat 1982;2:139-50
6. Bohnet HG, Bertram M. Der perioperative Hormonspiegel bei perimenopausalen Patient-innen mit gutartigen Veränderungen der Brust und ihre Beeinflußbarkeit durch verschiedene Hormontherapien. Gynäkologe 1989;22:255-61
7. Cancer Committee of the College of American Pathologists. Consensus Meeting. Is 'fibrocystic disease' of the breast precancerous? Arch Pathol Lab Med 1986;110:171-3
8. SAS Institute. SAS User's Guide: Statistics, Version 5. Cary, NC: SAS Institute, 1985
9. Dixon MJ, McDonald RA, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. Lancet 1999;335:1742-5
10. Carlström K, Döberl A, Gershagen S, et al. Elevated peripheral levels of androgens and some steroid sensitive plasma proteins in patients with severe fibrocystic breast disease. Act Obstet Gynecol Scand 1984;123(Suppl):157
11. Von Fournier D, Kubli F, Junkermann H, et al. Medikamentöse und operative Therapie der Mastopathie in Abhängigkeit vom Entartungsrisiko. Frauenarzt 1984;25:127-39
12. London R, Sunderam GS, Goltstein PJ. Medical management of mammary dysplasia. Obstet Gynecol 1982;59:519-23
13. Dennerstein L, Morse C, Gotts G, et al. Treatment of premenstrual syndrome, a double-blind trial of dydrogesterone. J Affect Disord 1986;11:199-205
14. Van der Meer YG, Benedek-Jaszmann LJ, Van Loenan AC. Effect of high dose progesterone on the premenstrual syndrome; a double-blind cross-over trial. J Psychosom Obstet Gynecol 1983;2:220-3
15. Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, picture and management. Am J Obstet Gynecol 1986;154:161-79
16. Ayers JWT, Gidwani GP. The 'luteal breast': hormonal and sonographic investigation of benign breast disease in patients with cyclic mastalgia. Fertil Steril 1983;40:779
17. Walsh PV, Bulbrock RD, Stell MP, et al. Serum progesterone concentration during luteal phase in women with benign breast disease. Eur J Cancer Clin Oncol 1984;20:1339-51
18. Tausk MJ, Thijssen JHH, van Wimersma Greidanus TB. Pharmakologie der Hormone, 4th edn. Stuttgart: Thieme, 1986
19. Watt-Boolsen S. Cyclisk Mastalgi. Copenhagen: FADL, 1981
20. Peters F, Schuth W, Scheunen B, et al. Serum prolactin levels in patients with fibrocystic breast disease. Obstet Gynecol 1984;64:381-5
21. Colin C, Gaspard U, Lambotte R. Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol. Arch Gynecol 1978;225:7-13
22. Von Fournier D, Kubli F, Bauer M, et al. Hochdosierte Gestagen - Langzeittherapie bei Korpuskarzinomen: Einfluß auf die Überlebenszeit. Geburtsh Frauenheilk 1981;41:266-9
23. Hoffmann V, Pedersen PA, Philipp J, et al. The effect of dydrogesterone on premenstrual symptoms. Scand J Prim Health Care 1988;6:179-83
24. Bancroft J, Backstrom T. Premenstrual syndrome. Clin Endocrinol 1985;22:313-36
25. Halbreich U, Endicott J. Possible involvement of endorphin withdrawl or imbalance in specific pre-menstrual syndromes and postpartum depression. Med Hypoth 1981;7:1045-58
26. Sanders D, Warner P, Backstrom T, et al. Mood, sexuality, hormones and the menstrual cycle. Changes in mood and physical state: description of subjects and method. Psychosom Med 1983;45: 487-501
27. Wood C, Larsen L, Williams R. Social and psychological factors in relation to premenstrual tension and menstrual pain. Aust NZ J Obstet Gynecol 1979;19:111-15
28. Berta L, Fraisia R, Brumma C, et al. Hormonal pattern and sex hormone globulin in plasma of women with cystic breast disease. In Angeli A, Bradlow HL, Dogliotti L, eds. Endocrinology in Cystic Benign Breast Disease. New York: Raven Press, 1983:123-6